MDMichael W. Dunne

Michael W. Dunne

*This is an algorithmically generated author record based on publicly available information.

Michael W. Dunne has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vitro activity and in vivo efficacy of sulopenem against Bacillus anthracis in inhalational anthrax mouse and rabbit models

    by Jennifer Chua, Annette M. Gray, Steven I. Aronin, Sailaja Puttagunta, Michael W. Dunne, Stephanie A. Halasohoris, Jade L. Spencer, Ashley L. Babyak, Majorie E. Torres, Bobby J. Curry, et al.

    Bacillus anthracis is a gram-positive, spore-forming bacterium and the etiological agent of anthrax. As a Tier 1 Select Agent, the pathogen can be isolated from the natural environment, and the endospore is a significant biological threat that can be produced in large quantities, stored, and disseminated by aerosolization. The intentional release of B. anthracis spores has the potential for mass casualties and is a serious threat to public and military health. Fluoroquinolones and tetracyclines are common antibiotics used for post-exposure prophylaxis and treatment in the United States (U.S.), whereas penicillin is the drug of choice throughout the rest of the world. However, these commonly used antibiotics may be contraindicated or suboptimal in a public health crisis. Thus, there is a need for novel medical countermeasures to be developed and tested against B. anthracis . Sulopenem is a broad-spectrum, orally bioavailable penem antibiotic recently approved in the U.S. for the treatment of uncomplicated urinary tract infections in women with limited therapeutic options. Here, we demonstrate that sulopenem has potent in vitro activity against both wild-type virulent B. anthracis strains, as well as biosafety level 2 surrogate strains resistant to current standards of care. Using human-equivalent dosing regimens, we show that sulopenem is highly protective in both the mouse and rabbit inhalational anthrax models. Together, these results support continued evaluation of this oral penem as a countermeasure for inhalational anthrax.

  • Open Access

    Applying Desirability of Outcome Ranking End Points

    by Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher

    To the Editor—We conducted a phase 3 trial in patients with uncomplicated urinary tract infection (UTI), comparing oral sulopenem etzadroxil + probenecid with oral ciprofloxacin [ 1], and we used the Food and Drug Administration's definition of overall success in studies of UTI, one that requires both clinical cure and microbiologic eradication. In the population of patients with uropathogens that were nonsusceptible to ciprofloxacin, sulopenem was superior to ciprofloxacin (62.6% vs 36.0%; difference, 26.6% [95% confidence interval (CI), 15.1%–37.4%]; P < .001). In the patients with ciprofloxacin-susceptible isolates, sulopenem was not noninferior to ciprofloxacin (66.8% vs 78.6%; difference, −11.8% [95% CI, −18.0 to −5.6). This difference could be attributed to a higher rate of asymptomatic bacteriuria after treatment in patients on sulopenem. In the analysis of all patients, sulopenem was noninferior to ciprofloxacin (65.6% vs 67.9%; difference, −2.3% [95% CI, −7.9 to 3.3]).


  • Open Access

    Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections

    by Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta

    Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta; Applying DOOR endpoint to


  • Open Access

    Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

    by Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher

    There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs. Patients with uUTI were randomized to 5 days of sulopenem or 3 days of ciprofloxacin. The primary endpoint was overall success, defined as both clinical and microbiologic response at day 12. In patients with ciprofloxacin-nonsusceptible baseline pathogens, sulopenem was compared for superiority over ciprofloxacin; in patients with ciprofloxacin-susceptible pathogens, the agents were compared for noninferiority. Using prespecified hierarchical statistical testing, the primary endpoint was tested in the combined population if either superiority or noninferiority was declared in the nonsusceptible or susceptible population, respectively. In the nonsusceptible population, sulopenem was superior to ciprofloxacin, 62.6% vs 36.0% (difference, 26.6%; 95% confidence interval [CI], 15.1 to 7.4; P <.001). In the susceptible population, sulopenem was not noninferior to ciprofloxacin, 66.8% vs 78.6% (difference, −11.8%; 95% CI, −18.0 to 5.6). The difference was driven by a higher rate of asymptomatic bacteriuria (ASB) post-treatment in patients on sulopenem. In the combined analysis, sulopenem was noninferior to ciprofloxacin, 65.6% vs 67.9% (difference, −2.3%; 95% CI, −7.9 to 3.3). Diarrhea occurred more frequently with sulopenem (12.4% vs 2.5%). Sulopenem was noninferior to ciprofloxacin in the treatment of uUTIs. Sulopenem was superior to ciprofloxacin in patients with uUTIs due to ciprofloxacin-nonsusceptible pathogens. Sulopenem was not noninferior in patients with ciprofloxacin-susceptible pathogens, driven largely by a lower rate of ASB in those who received ciprofloxacin. NCT03354598.


  • Open Access

    Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial

    by Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta

    Background: Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. The availability of both intravenous (IV) and oral formulations will facilitate earlier hospital discharge. Methods: Hospitalized adults with pyuria, bacteriuria, and signs and symptoms of complicated urinary tract infection (cUTI) were randomized to 5 days of IV sulopenem followed by oral sulopenem etzadroxil/probenecid or 5 days of IV ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate, depending on uropathogen susceptibility. The primary end point was overall combined clinical and microbiologic response at the test-of-cure visit (day 21). Results: Of 1392 treated patients, 444 and 440 treated with sulopenem and ertapenem, respectively, had a positive baseline urine culture and were eligible for the primary efficacy analyses. Extended-spectrum β-lactamase-producing organisms were identified in 26.6% of patients and fluoroquinolone-nonsusceptible pathogens in 38.6%. For the primary end point, noninferiority of sulopenem to the comparator regimen was not demonstrated, 67.8% vs 73.9% (difference, −6.1%; 95% confidence interval, −12.0 to −.1%). The difference was driven by a lower rate of asymptomatic bacteriuria in the subgroup of ertapenem-treated patients who stepped down to ciprofloxacin. No substantial difference in overall response was observed at any other time point. Both IV and oral formulations of sulopenem were well-tolerated and compared favorably to the comparator. Conclusions: Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin. Both formulations of sulopenem were well-tolerated. Clinical Trial Registration: NCT03357614.


  • Open Access

    Peter of Ireland and Berthold of Moosburg on First Being, First Life, and First Mind

    by Michael W. Dunne

    "Chapter 13 Peter of Ireland and Berthold of Moosburg on First Being, First Life, and First Mind" published on 02 Aug 2021 by Brill.

  • From longitudo vitae to prolungatio vitae

    by Michael W. Dunne

    It has been long surmised that Peter of Ireland’s (Petrus de Hibernia, fl. 1240–60) interest in natural philosophy derived from his initial education in Oxford before arriving at the University of Naples towards the middle of the thirteenth century. In his commentary on Aristotle’s De longitudine et brevitate vitae, Peter certainly makes use of many Aristotelian sources, but what is also significant is how he blends his Aristotelian natural philosophy with many medical authors in order to explore length and shortness of life. This influence may derive from the nearby School of Salerno or at least to the availability of translations such as those of Constantine the African. This chapter explores the uses made by Peter of such texts, as well as their wider significance in relation to the medieval debate and Roger Bacon’s contribution.

  • Open Access

    An Assessment of Skin Lesion Measurement Techniques for Use in Clinical Trials of Acute Bacterial Skin and Skin Structure Infections

    by Michael W. Dunne, Anita Das, George H. Talbot

    Background: Limited data are available to support a reproducible measurement technique that could be used to assess the response of a skin lesion associated with a bacterial infection to antibacterial therapy. Methods: This multicenter, observational study enrolled patients with a major cutaneous abscess, a traumatic wound or surgical site infection, or a cellulitis. The primary objective was to characterize the intra- and inter-observer variability inherent in measuring the size of the erythema associated with the presenting skin infection. At least two observers made ruler measurements of the infection site with the length of the infection measured as the longest dimension of the erythematous area and width measured as the largest dimension perpendicular to the longest length. Intra- and inter-observer variability was determined by the intraclass correlation coefficient (ICC). Photographs, tracings, and thermal imaging were also performed. Results: The intra - observer ICC (95% CI) for lesion area as measured by ruler was 0.999 (0.998, 0.999), suggesting only a very small amount of the variability was due to measurement error. The difference in mean lesion area measurements by the same observer was <1%. The inter-observer ICC (95% CI) for lesion area as measured by ruler was 0.990 (0.981, 0.995) suggesting that the results between observers were also highly reliable. Conclusions: Measurement of infection area as defined by erythema and measured by ruler shows excellent intra- and inter-observer reliability and can be used in future clinical trials of acute bacterial skin infections.

  • Open Access

    Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

    by Michael W. Dunne, George H. Talbot, Helen W. Boucher, Mark Wilcox, Sailaja Puttagunta

    Introduction Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for daily dosing. Objective The objective of these analyses was to compare the adverse event profile of dalbavancin with that of the comparator agents in the treatment of skin and skin structure infections. Methods Data on adverse events and laboratory assessments collected from 3002 patients enrolled in seven late-stage, randomized clinical trials were analyzed for patients receiving dalbavancin or a comparator antibiotic. Results Overall adverse event rates were similar or lower for patients receiving dalbavancin (799/1778; 44.9 %) compared with those receiving comparator agents (573/1224; 46.8 %, p = 0.012). The most common treatment-emergent adverse events were nausea, headache, diarrhea, constipation, vomiting, rash, urinary tract infection, pruritus, and insomnia. The duration and timing of the onset of adverse events were similar for patients receiving dalbavancin relative to the comparators. Conclusion Dalbavancin exhibits a favorable overall safety profile for treatment of acute bacterial skin and skin structure infections due to Gram-positive bacteria.